Search Results

I watched @Hazel's video and all I saw was a privileged white person being a gatekeeper of the most important information this forum has to offer....

I’m not sure this will be addressed in their next conference. This study was based on a Safety dose, not a Therapeutic dose. They still had to...

“Although further development of the GSI inhibitor is required, the REGAIN project has helped shape the developmental and regulatory processes...

The lower the Hz number, the farther the drug has to travel. In the example above, 3500Hz is a considerably longer distance FX-322 has to go to...

I agree, if we can ask about this in the upcoming Tinnitus Talk Podcast with Frequency Therapeutics that would be amazing. I might be reaching...

Frequency Therapeutics updated the slides to their corporate presentation. One meaningful change I noticed is on slide 15. The diagram now shows...

I think it would be really great if we had the Tinnitus Talk Podcast reach out to Jeff Karp. He’s extremely receptive and a kind human being and I...

Just wanted to add to this list that someone asked a question with regards to “durability” of the improvements seen in treated patients and both...

Did they convey how much they increased the concentration from the phase 1b trial, or did they convey how much they’re increasing the volume?...

I guess I had higher hopes this could help people with hearing loss lower than 4000 Hz.

Frequency Therapeutics may be backtracking a little bit. On Slide 11: “FX-322 designed to enable hearing in higher frequency ranges critical for...

Frequency posted a detailed corporate presentation this morning: https://investors.frequencytx.com/static-files/6d161090-16f5-49f4-9606-8caceb5a88a1

If you hear back from them, can you ask them about the volume of drug they’ll be injecting and ask them if they’ve increased the concentration of...

It infuriates me that there’s no information with regards to the volume or concentration of FX-322 being injected in the 4 investigational groups.

Kicking off:...

I’ve thought a lot about Astella after reading the IPO document. Here are some of my thoughts: 1) I call bullshit on Frequency Therapeutics not...

I think there’s room to be optimistic here. Frequency’s largest administered dose in this study was 0.2 milliliters of FX-322. Audion stated in...

In cases of cisplatin induced ototoxicity, yes, but in cases of gentimicen I believe in only kills the hair cells themselves. I could be wrong...

In the 2nd diagram, what year was this created? Where is the literature you pulled this from? I’m curious, did the verbiage mention what happens...

I honestly believe there’s hope for FX-322 treating ototoxicity damage. In their 2017 paper they treated hair cells that were deliberately damaged...

I’m sorry for your situation. Have you given any thought to FX-322? They’re gonna be enrolling for Phase 2a here in the next couple months. Based...

This individual’s anecdote is here-say, and this anecdote is supported by an “anonymous source”, and within this anecdote there exists inaccurate...

The drug isn’t a gel-like substance, it’s a liquid: “This is the first time the study drug LY3056480 will be tested in people. The study drug is...

This article was written based off an interview that was done yesterday, but they specifically state in the article that Frequency Therapeutics is...

Audion is REGAIN

The presentation Frequency is doing in September is only going to be 5min long. That’s a less than inspirational time slot.

“There has been some success in hair cell regeneration following Wnt and Notch modulation in the mature mammalian cochlea.34,52 However, it is...

https://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(19)30111-X.pdf Review of current pharmacological approaches to...

I think it’s important to point out that there are still no results posted from the Phase I they did in Australia well over a year ago, so...

I guess what I can’t wrap my head around is why Frequency didn’t attempt a multiple dose approach in this 1.5 study if they had any inclination...

@Aaron123 welcome back man, it’s good to see you.

I get that, but I think what I’m trying to say more clearly is this: David Lucchino mentioned in an interview that a 10 dB improvement is a...

I agree with your logic to some degree, but I think it’s important to note that Frequency Therapeutics for the longest time pushed this whole...

They can start Phase II before the Ib results get posted to the public. Unless something negative happened in Ib.

They still technically have no drugs in their pipeline. Just an investigational drug to combat ototoxicity. Decibel is a very long way off from...

I live in San Francisco and I’ve tried reaching out to the venue administrators as well as the JP Morgan contacts for this event. This conference...

Molecular characterization and prospective isolation of human fetal cochlear hair cell progenitors https://www.nature.com/articles/s41467-018-06334-7

@Jason37 @Deathtotinni Since the both of you almost made it into the trials, can either of you provide us information on what specific unit of...

Hang in there. 2019 is going to be the Year of the Ear. A lot of movement will come to fruition this coming calendar year. Keep your head up.

Can you elaborate further on the bit about dosage? Can you elaborate further on why they believe that altering the mechanical parts of your inner...

This thread is going off on an extreme tangent. Unfortunately, I’m going to contribute an opinion that feeds into this against my better...

I didn’t see this posted yet, but Otonomy updated their website with the PowerPoint/Slideshow from the post @Tigo provided earlier:...

Mild hearing loss and moderate hearing loss are part of the current criterion for their target group as it stands today, and these are the two...

I was just about to post this link, but here are a few things Lucchino mentioned: - Frequency Therapeutics won’t be looking at the data from this...

This is a research update forum. This is NOT a support forum. There is a forum here coincidentally called “Support”. Please find your way there.

This is misinformation at best. FX-322 does NOT create new supporting cells. FX-322 makes a copy of an existing supporting cell, and that...

I, too, am most worried about what @Contrast said. That a healthy HC, but with retracted ribbon synapses, will not get regenerated, thus this drug...

Thank you.

Does anyone have another means of contacting him? Social media, email, messenger pigeon?

For what it’s worth, based on Frequency’s latest press release they mentioned pushing this drug into a “Phase 2a” early next calendar year. I...

Will McClean briefly talks about hearing restoration and other applications of his work:...

This is all very compelling information on Frequency Therapeutics. Keep up the great content guys.

Frequency has stated on multiple occasions that FX-322 is comprised of inexpensive materials that are readily available and easy to manufacture....

https://endpts.com/nea-5am-back-a-50m-play-to-steer-gene-therapies-to-the-clinic-at-akouos-the-latest-startup-in-hearing/ Akouos has...

https://www.in-pharmatechnologist.com/Article/2018/08/09/Frequency-sounds-out-progenitor-cell-activation-for-hearing-restoration Carl LeBel of...

http://frequencytx.com/news-events/news-events-press-release-08-14-2018.php Frequency has added additional scientists to their regenerative...

I think it’s also important to keep in mind, too, that Frequency is a privately funded startup that has MIT’s and Harvard’s brightest scientists...

I think there’s reason to be very positive here. 1/3 of the participants in this 1.5 trial are receiving a high dose. This is VERY significant and...

3 groups. High Dose: 8 participants Low Dose: 8 participants Placebo: 8 Participants That’s a 67% chance of receiving the drug. Also, I...

Jeff Karp stated in a podcast last year that they expect the treatment to have long lasting effects if it works in the first place. We also...